EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy

Kaizhen Wang, Xiangyu Zhang iD, Yao Cheng, Zhihao Qi, Ke Ye, Kuojun Zhang iD, Sheng Jiang iD, Yi Liu iD, Yibei Xiao, Tianyu Wang iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kaizhen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Postdoctoral Research Foundation of China, Jiangsu Planned Projects for Postdoctoral Research Funds, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor cells can evade immune surveillance through overexpressing programmed cell death-ligand 1 (PD-L1) to interact with programmed cell death-1 (PD-1). Besides, tumor-intrinsic PD-L1 is involved in tumor progression without interaction with PD-1, which provides more challenges for the discovery of PD-L1 inhibitors. Herein, we report the discovery of novel PD-L1 inhibitors using the fragment coupling strategy. Among them, B9 was found to inhibit the PD-1/PD-L1 interaction with the best IC50 value of 1.8 ± 0.7 nM. Beyond the blockade of the PD-1/PD-L1 axis, B9 promotes the dimerization, internalization, and degradation of PD-L1. Furthermore, B9 displayed high in vivo antitumor efficacy in the CT26 mouse model and activated the immune microenvironment and induced PD-L1 degradation of PD-L1 in the tumor. These results show that B9 is a promising lead PD-L1 inhibitor through the blockade of PD-1/PD-L1 interaction and functional inhibition of the PD-L1 signal pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsB7-H1 AntigenAnimalsMiceDimerizationProgrammed Cell Death 1 ReceptorSignal Transduction

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

ORCID-Profile: Xiangyu Zhang, Kuojun Zhang, Sheng Jiang, Yi Liu, Tianyu Wang

Förderung

  • Postdoctoral Research Foundation of China
  • Jiangsu Planned Projects for Postdoctoral Research Funds
  • Ministry of Science and Technology of the People's Republic of China
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Wang, K., Zhang, X., Cheng, Y., Qi, Z., Ye, K., Zhang, K., Jiang, S., Liu, Y., Xiao, Y., & Wang, T. (2023). Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01534

Vancouver

Wang K, Zhang X, Cheng Y, Qi Z, Ye K, Zhang K, et al. Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01534

BibTeX
@article{Wang2023,
  author = {Wang, Kaizhen and Zhang, Xiangyu and Cheng, Yao and Qi, Zhihao and Ye, Ke and Zhang, Kuojun and Jiang, Sheng and Liu, Yi and Xiao, Yibei and Wang, Tianyu},
  title = {Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01534}
}
Kostenlos starten →